Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from the Mexican Oncology Study Group.

被引：0
|
作者：
Torrecillas, L [1 ]
Soto, C [1 ]
Cervantes, G [1 ]
Benitez, H [1 ]
Acosta, A [1 ]
Cortes, P [1 ]
Gonzalez, F [1 ]
Zamora, R [1 ]
Rodriguez, G [1 ]
Silva, A [1 ]
Leoner, C [1 ]
Sauza, F [1 ]
Suarez, T [1 ]
Tokunaga, J [1 ]
Erazo, A [1 ]
Talavera, J [1 ]
机构：
[1] IMSS, Mexico City, DF, Mexico
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S200 / S200
页数：1
相关论文
共 50 条
  • [41] Frontline docetaxel (T) capecitabine M combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study.
    Chun, JH
    Lee, HG
    Lee, ES
    Kim, E
    Oh, JH
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 71S - 71S
  • [42] Capecitabine (C) and vinorelbine (V) in elderly patients (pts.) with metastatic breast cancer (MBC) as 1st line treatment:: a prospective multicentre phase II study of the NOGGO breast cancer study group.
    Koehler, U.
    Luhn, B.
    Kleine-Tebbe, A.
    Goehler, T.
    Blohmer, J-U
    Schroeder, J.
    Sieg, K.
    Krocker, J.
    Hindenburg, H. J.
    Hielscher, C.
    Koelsch, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S285 - S286
  • [43] Activity of oral irinotecan ORO in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results.
    Vukeljia, S
    O'Shaughnessy, J
    Campos, S
    Vahdat, L
    Blum, J
    Yardley, D
    Mainwaring, T
    Senecal, F
    Benner, R
    Denis, L
    Perez, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 19S - 19S
  • [44] Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
    Kahan, Z.
    Gil-Gil, M.
    Ruiz-Borrego, M.
    Carrasco, E. M.
    Ciruelos, E. M.
    Munoz, M.
    Bermejo De Las Heras, B.
    Margeli Vila, M.
    Anton, A.
    Casas, M.
    Calvo, L.
    de la Haba, J.
    Ramos, M.
    Alvarez-Lopez, I.
    Gal-Yam, E.
    Gautier, E.
    Corsaro, M.
    Rodrigalvarez, G.
    Zielinski, C.
    Martin Jimenez, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S66 - S67
  • [45] Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy: A phase I dose-finding study.
    Susnjar, S
    Bosnjak, S
    Radulovic, S
    Stevanovic, J
    Gajic-Dobrosavljevic, M
    Kreacic, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 90S - 90S
  • [46] Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)
    Tomova, Antoaneta
    Bartsch, Rupert
    Brodowicz, Thomas
    Tzekova, Valentina
    Timcheva, Constanta
    Wiltschke, Christoph
    Gerges, Dany Abi
    Pawlega, Jan
    Spanik, Stanislav
    Inbar, Moshe
    Zielinski, Christoph C.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 169 - 176
  • [47] Capecitabine+3-weekly oxaliplatin (XELOX) vs. capecitabine followed by XELOX after progression as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC): A Mexican oncology study group phase III trial
    Rubio, Jaime
    Reyes, Salvador
    Soto, Celia
    Torrecillas, Laura
    Gonzalez, Fernando
    Castruita, Ana
    Cabrera, Paula
    Cervantes, Guadalupe
    Perez, Laura
    Hernandez, David
    ANNALS OF ONCOLOGY, 2006, 17 : 120 - 120
  • [48] Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)
    Antoaneta Tomova
    Rupert Bartsch
    Thomas Brodowicz
    Valentina Tzekova
    Constanta Timcheva
    Christoph Wiltschke
    Dany Abi Gerges
    Jan Pawlega
    Stanislav Spanik
    Moshe Inbar
    Christoph C. Zielinski
    Breast Cancer Research and Treatment, 2010, 119 : 169 - 176
  • [49] Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt
    Kandil, A.
    Hamada, E.
    Moawad, M.
    El Arab, L. Ezz
    Metwalli, H.
    Bathiouny, M.
    Mourad, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S351
  • [50] A Phase I/II study of capecitabine (X) combined with oral vinorelbine IN) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Delcambre, C.
    Veyret, C.
    Levy, C.
    Switsers, O.
    Allouache, D.
    Raban, N.
    Grellard, J. M.
    Leconte, A.
    Delozier, T.
    EJC SUPPLEMENTS, 2005, 3 (02): : 118 - 118
12345